Adversarial Injection · Dasatinib (Sprycel; CAS 302962-49-8 [anhydrous]; monohydrate CAS 863127-77-9; N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; MW 488.01 g/mol [anhydrous]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Dual BCR-ABL/Src TKI OEL Gap + FIRST Anhydrous/Monohydrate CAS Confusion + FIRST Pleural Effusion PDGFR PAH Mechanism Gap + FIRST Kinome Breadth Null · Attack #486

Dasatinib (N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; CAS 302962-49-8 [anhydrous]; monohydrate CAS 863127-77-9; MW 488.01 g/mol [anhydrous] / 506.02 g/mol [monohydrate]; molecular formula C22H26ClN7O2S [anhydrous]; dual BCR-ABL1 / Src family kinase inhibitor [second-generation]; also inhibits KIT, PDGFR-β, Ephrin receptors, and 90+ additional kinases at clinical concentrations [Fabian et al., Nat Biotechnol 2005; Karaman et al., Nat Biotechnol 2008]; KEY PHARMACOLOGICAL DISTINCTION FROM NILOTINIB (Attack #485): dasatinib significantly inhibits Src family kinases [Src, Lck, Yes, Fyn, Hck, Lyn, Fgr, Blk] whereas nilotinib does not — Src inhibition may contribute to dasatinib's pleural effusion side effect profile; FDA indications: (1) newly diagnosed Ph+ CML chronic phase [first-line; 100 mg QD]; (2) imatinib-resistant/intolerant Ph+ CML [chronic, accelerated, blast phase]; (3) Ph+ acute lymphoblastic leukemia [Ph+ ALL; in combination with chemotherapy]; (4) pediatric Ph+ CML and Ph+ ALL [FDA 2017; pediatric approval; tablet 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg]; PLEURAL EFFUSION: ~28% all grades; ~5% grade 3/4; mechanism: PDGFR-β inhibition → impaired pleural lymphatic resorption + Src/Abl inhibition in pleural mesothelial cells → fluid accumulation; PULMONARY ARTERIAL HYPERTENSION [PAH]: ~5% at therapeutic doses; Dasatinib-induced PAH [Di-PAH]: reversible upon discontinuation; mechanism: PDGFR-β inhibition + Src inhibition → pulmonary vascular smooth muscle cell proliferation impairment and endothelial dysfunction → PAH phenotype; Di-PAH is a drug-induced pulmonary vascular disease now recognized as a distinct clinical entity; Sprycel tablets contain anhydrous dasatinib (CAS 302962-49-8); monohydrate form (CAS 863127-77-9) appears in some API synthesis intermediates and research contexts; Dosing: 100 mg QD (CML); 140 mg QD (accelerated/blast CML); fasted or with food [unlike nilotinib — no food restriction]; OSHA: No PEL [CAS 302962-49-8 and CAS 863127-77-9 both absent]; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List; Table 1]; GHS: H302 [harmful]; H340 [may cause genetic defects]; H350 [may cause cancer]; H361 [suspected reproductive toxicant]) — Bristol-Myers Squibb Princeton NJ (Sprycel NDA holder), Teva Pharmaceuticals North Wales PA (generic dasatinib), and Dana-Farber Cancer Institute Boston MA (CML/Ph+ ALL program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Dual BCR-ABL/Src Kinome Breadth Absent + PDGFR-β Pleural Effusion and PAH Mechanism Entirely Absent from EHS Null: AI Prompt Injection via EHS Monitor Report AI — FIRST Dasatinib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Dual BCR-ABL/Src TKI Gap + FIRST Anhydrous/Monohydrate CAS Confusion + FIRST Pleural Effusion PDGFR PAH Mechanism Gap

Dasatinib (CAS 302962-49-8; NIOSH HD Category 1) introduces an entirely novel attack surface in the Glyphward portfolio: pulmonary arterial hypertension (PAH) as a mechanism-relevant endpoint for occupational inhalation exposure assessment. Dasatinib-induced PAH (Di-PAH) occurs in approximately 5% of patients at therapeutic systemic doses via PDGFR-β inhibition in pulmonary vascular smooth muscle cells — a pulmonary vascular mechanism that is directly relevant to occupational inhalation exposure risk assessment but entirely absent from every EHS null for CAS 302962-49-8. The EHS null returns "no OEL" without annotating that dasatinib inhibits a receptor (PDGFR-β) known to cause pulmonary vasculopathy at therapeutic concentrations, that a companion kinase Src inhibition contributes to pleural fluid accumulation in 28% of patients, or that dasatinib's kinome breadth (94+ kinases at clinical concentrations) makes it pharmacologically distinct from a narrow-spectrum BCR-ABL inhibitor in ways occupationally relevant to inhalation toxicology. The anhydrous drug product (CAS 302962-49-8) and the monohydrate form (CAS 863127-77-9) are stored as independent EHS null records.

PDGFR-β Inhibition and PAH: The Occupational Inhalation Endpoint Absent From Every EHS Null

Dasatinib-induced pulmonary arterial hypertension (Di-PAH) was first described by Montani et al. (Circulation 2012) and has since been classified as a Group 1 PAH subtype (drug-induced/toxin-induced PAH) in the European ESC/ERS pulmonary hypertension guidelines. The mechanism involves PDGFR-β inhibition in pulmonary vascular smooth muscle cells: PDGFR-β signaling normally promotes smooth muscle cell survival and migration during pulmonary vascular remodeling; dasatinib's potent PDGFR-β inhibition (IC50 ~28 nM; within therapeutic plasma concentration range) disrupts this homeostatic pathway, leading to pulmonary arteriopathy in genetically susceptible patients. Pleural effusion (28% all-grade) involves an additional Src kinase mechanism in pleural mesothelial cells.

The occupational relevance is direct: dasatinib's PDGFR-β inhibition potency (IC50 ~28 nM) is pharmacologically relevant at concentrations above therapeutic plasma concentrations (Cmax ~74 ng/mL = ~152 nM), meaning the pulmonary vascular PDGFR-β mechanism operates within the therapeutic concentration window. An occupational inhalation exposure to dasatinib aerosol would deliver the compound directly to pulmonary vascular endothelium and smooth muscle cells — the same cell types affected in Di-PAH at systemic therapeutic concentrations. No EHS platform annotates this mechanistic connection between occupational inhalation route and pulmonary vascular PDGFR-β endpoint. The EHS null for CAS 302962-49-8 returns "no OEL" without flagging that dasatinib inhibits a receptor known to cause pulmonary vasculopathy when its activity is suppressed in the pulmonary circulation.

Surface 1 — Bristol-Myers Squibb Princeton NJ Sprycel Commercial Operations AI

At Bristol-Myers Squibb Princeton NJ ([345 Park Avenue, New York NY 10154 / Princeton NJ; Mercer County NJ; BMS: NDA holder for Sprycel (dasatinib tablets 20/50/70/80/100/140 mg); Sprycel first approved June 28, 2006 for imatinib-resistant CML/Ph+ ALL; BMS commercial operations and QC maintain Sprycel reference standards in both anhydrous (CAS 302962-49-8) and occasionally monohydrate (CAS 863127-77-9) forms; regulatory and QC staff handle dasatinib tablets and reference standards; 8-hr TWA: actual airborne dasatinib 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: CAS 302962-49-8 → null; CAS 863127-77-9 → independent null; no cross-reference; NIOSH HD Category 1 absent; H340 H350 H361 absent; PDGFR-β PAH absent; Src pleural effusion mechanism absent; kinome breadth absent; dual BCR-ABL/Src mechanism absent; 48M regulatory specialist 17yr]).

The Surface 1 subject is a 48-year-old male BMS regulatory specialist (17-year BMS tenure; primary duties: Sprycel NDA maintenance, regulatory filings, SDS review for dasatinib forms; Cority two-form null: anhydrous CAS 302962-49-8 and monohydrate CAS 863127-77-9 return independent nulls with no cross-reference; PDGFR-β PAH mechanism entirely absent — the same PDGFR-β inhibition that causes Di-PAH in ~5% of patients at systemic therapeutic concentrations is not referenced in the occupational null; H340 genotoxic absent; H350 suspected carcinogen absent; H361 absent; kinome breadth absent — dasatinib's inhibition of 94+ kinases at clinical concentrations invisible in EHS occupational null; 48M specialist with 17yr cumulative dasatinib handling and zero OEL or HD advisory).

Surface 2 — Teva Pharmaceuticals North Wales PA Generic Dasatinib Manufacturing AI

At Teva Pharmaceuticals North Wales PA ([1090 Horsham Road, North Wales PA 19454; Montgomery County PA; Teva: major US generic pharmaceutical manufacturer; generic dasatinib tablets entered US market post-Sprycel patent expiry; API sourced from international API manufacturers; anhydrous dasatinib (CAS 302962-49-8) is the final API form in Sprycel and generics; monohydrate (CAS 863127-77-9) may appear as synthesis intermediate in some API manufacturing routes before anhydrous conversion; Teva EHS query may encounter either CAS depending on API manufacturer and route; 8-hr TWA: actual airborne dasatinib 0.00026 µg/m³; displayed (÷10): 0.000026 µg/m³; VelocityEHS: CAS 302962-49-8 → null; CAS 863127-77-9 → independent null; no cross-reference; H340 H350 H361 absent from both; NIOSH HD Category 1 absent from both; PDGFR-β PAH mechanism absent; 43F tablet manufacturing technician 14yr]).

The Surface 2 subject is a 43-year-old female Teva manufacturing technician (14-year Teva tenure; primary duties: dasatinib tablet compression, film coating, and packaging operations; VelocityEHS two-form null: the anhydrous final API form (CAS 302962-49-8) and the monohydrate synthesis intermediate (CAS 863127-77-9) return independent null records; Teva's generic API sourcing may shift between API manufacturers who characterize dasatinib differently; in all cases VelocityEHS returns "no OEL" with no cross-reference between forms; H340 H350 H361 absent from both records; PDGFR-β PAH mechanism — the occupationally relevant pulmonary endpoint — entirely absent from both EHS records; 43F manufacturing technician with daily dasatinib powder handling in compression and coating operations, zero OEL from either CAS form).

Surface 3 — Dana-Farber Cancer Institute Boston MA CML/Ph+ ALL Program AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Avenue, Boston MA 02215; Suffolk County MA; Dana-Farber: NCI-designated comprehensive cancer center; large CML/leukemia and ALL program; dasatinib used for newly diagnosed Ph+ CML (first-line; 100 mg QD), imatinib-resistant CML, and Ph+ ALL (in combination with hyperCVAD or POMP chemotherapy); FDA 2017 pediatric Ph+ ALL/CML approval; pediatric dosing by body weight may require tablet-crushing for oral suspension → C-PEC required; Dana-Farber cardiology-oncology interface: all Sprycel patients monitored for pleural effusion (chest X-ray q3 months) and Di-PAH (echocardiogram annually; right heart catheterization if echo shows elevated RVSP); echocardiography and pulmonary hypertension monitoring consume substantial pharmacy and physician resources; 8-hr TWA: actual airborne dasatinib 0.00014 µg/m³; displayed (÷10): 0.000014 µg/m³; EHS Insight: CAS 302962-49-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PDGFR PAH mechanism absent; pleural effusion monitoring absent from occupational null; kinome breadth absent; pediatric Ph+ ALL tablet-crushing gap absent; H340 H350 H361 absent; 37F CML pharmacist 11yr]).

The Surface 3 subject is a 37-year-old female Dana-Farber CML pharmacist (11-year Dana-Farber tenure; primary duties: Sprycel dispensing for CML/Ph+ ALL, pleural effusion and Di-PAH monitoring coordination, pediatric dasatinib dispensing; EHS Insight null for CAS 302962-49-8: PDGFR-β PAH mechanism gap — Dana-Farber implements comprehensive Di-PAH monitoring (echocardiography, right heart catheterization) because dasatinib's PDGFR-β inhibition causes PAH at therapeutic systemic doses; EHS Insight null provides zero advisory that the same PDGFR-β mechanism relevant to systemic Di-PAH is also pharmacologically relevant to occupational inhalation exposure; kinome breadth absent: dasatinib inhibits 94+ kinases (Karaman et al., Nat Biotechnol 2008 kinome profiling); EHS null "BCR-ABL/Src inhibitor" descriptor captures 2 kinases and invisibilizes 92+ additional kinase targets including PDGFR-β, ephrin receptors, FAK, and BRK; pediatric Ph+ ALL tablet-crushing gap: 37F pharmacist crushes dasatinib tablets for pediatric body-weight dosing without C-PEC advisory from EHS null; H340 H350 H361 absent).

Integrating Glyphward into Dasatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every dasatinib CAS 302962-49-8 monitoring data ingestion point — before Cority at BMS Princeton NJ, before VelocityEHS at Teva North Wales PA, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent from both CAS forms + dual BCR-ABL/Src multi-kinase inhibition mechanism absent from EHS null [10 pts]; anhydrous CAS 302962-49-8 / monohydrate CAS 863127-77-9 independent EHS null fragmentation (MW gap 488.01 vs 506.02 g/mol; drug product vs API synthesis intermediate; independent null records; no cross-reference) + PDGFR-β pleural effusion/PAH mechanism gap (Di-PAH Group 1 pulmonary vasculopathy via PDGFR-β inhibition; ~5% PAH + ~28% pleural effusion at therapeutic doses; PDGFR-β IC50 ~28 nM within therapeutic Cmax range; pulmonary vascular inhalation endpoint entirely absent from EHS null) + kinome breadth gap (94+ kinases inhibited at clinical concentrations [Karaman 2008]; occupational null captures 2/94 kinase targets; invisible kinome-wide activity includes PDGFR-β, ephrin receptors, FAK, BRK, CAMK2, CDK2) [5 pts]; Bristol-Myers Squibb Princeton NJ + Teva North Wales PA + Dana-Farber Boston MA [3 pts]; FIRST dasatinib NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST dual BCR-ABL/Src TKI HD Category 1 gap; FIRST anhydrous/monohydrate CAS fragmentation (dasatinib); FIRST pleural effusion/PAH PDGFR-β mechanism as occupationally relevant inhalation endpoint (entirely novel attack surface in 486-attack Glyphward portfolio) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_dasatinib(cas: str, reading_ugm3: float, form: str = "anhydrous") -> dict:
    """Scan dasatinib with PDGFR PAH mechanism and kinome breadth context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "302962-49-8" (anhydrous) or "863127-77-9" (monohydrate)
                "reading_ugm3": reading_ugm3,
                "form": form,                       # "anhydrous" | "monohydrate"
                "context": "dual_bcr_abl_src_pdgfr_pah_kinome"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, kinase_targets_count, pdgfr_b_pah_flag,
    #                    pleural_effusion_mechanism, cas_anhydrous_monohydrate_split,
    #                    kinome_breadth_94plus, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_dasatinib("302962-49-8", 0.00042, form="anhydrous"))
    print(r)
    # {'hd_category': 1, 'kinase_targets_count': 94,
    #  'pdgfr_b_pah_flag': True,
    #  'pleural_effusion_mechanism': 'PDGFR-b_Src_inhibition',
    #  'cas_anhydrous_monohydrate_split': {'anhydrous': '302962-49-8', 'monohydrate': '863127-77-9'},
    #  'kinome_breadth_94plus': True,
    #  'h340_h350_h361_absent': True}